Johnson & Johnson (JNJ) Q1 2025 Earnings
How Did JNJ Stock React to Q1 2025 Earnings?
S&P 500 over the same 30 days: +10.53%.
Did JNJ Beat Earnings? Q1 2025 Results
Yes. Johnson & Johnson reported Q1 2025 earnings of $2.77 a share on Apr 15, 2025, beating the $2.58 consensus estimate by 7.3%. Revenue was $21.9B against a $21.6B estimate.
Johnson & Johnson opened 2025 with a convincing beat across the board, posting first-quarter adjusted EPS of $2.77 against a consensus of $2.58 — a 7.34% beat — while revenue of $21.89 billion edged past estimates by 1.48% and grew 2.4% year-over-year. The headline driver was a surging oncology franchise within Innovative Medicine, where DARZALEX alone contributed $3.24 billion in sales, up 20.3%, helping offset an approximately 810 basis point headwind from STELARA biosimilar erosion. MedTech added $8.02 billion, lifted by cardiovascular strength including the newly acquired Shockwave platform. For investors <a href="https://247wallst.com/investing/2025/07/16/johnson-johnson-nyse-jnj-live-earnings-updates-will-the-dividend-champion-deliver/">watching the dividend champion closely</a>, J&J also announced a 4.8% dividend increase — its 63rd consecutive year of raises — alongside a commitment to more than $55 billion in U.S. investment. Looking ahead, the company maintained its adjusted EPS guidance of $10.50–$10.70 for full-year 2025, absorbing tariff costs and acquisition dilution while integrating Intra-Cellular Therapies' CAPLYTA into its growing neuroscience portfolio.
- DARZALEX worldwide sales grew 20.3% to $3.2B driven by strong demand in oncology
- CARVYKTI worldwide sales more than doubled to $369M
- TREMFYA grew 18.2% to $956M with Crohn's disease approval expanding addressable market
- SPRAVATO grew 41.9% to $320M in neuroscience
- XARELTO grew 33.3% to $690M in cardiovascular
- MedTech Cardiovascular grew 16.4% driven by Abiomed and Shockwave acquisition
- STELARA declined 33.7% to $1.6B representing ~810 basis points headwind from biosimilar competition
- U.S. sales grew 5.9% while international declined 1.8% due to currency headwinds
“The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance.”
Johnson & Johnson CEO, on the earnings call
What Was Johnson & Johnson's Outlook in Q1 2025?
J&J updated full-year 2025 guidance: adjusted operational sales growth of 2.0%–3.0% (midpoint 2.5%), operational sales of $91.6B–$92.4B (midpoint $92.0B, 3.3%–4.3% growth), estimated reported sales of $91.0B–$91.8B (midpoint $91.4B, 2.6%–3.6% growth). Adjusted operational EPS (diluted) of $10.50–$10.70 (midpoint $10.60, 5.2%–7.2% growth). Adjusted reported EPS (diluted) of $10.50–$10.70 (midpoint $10.60, 5.2%–7.2% growth). The guidance increase to operational sales reflects the addition of CAPLYTA following the Intra-Cellular Therapies acquisition. The company maintained its adjusted EPS outlook despite absorbing tariff costs, acquisition dilution, and updated foreign exchange headwinds.
JNJ YoY Financials
| Metric | Q1 2025 | Q1 2024 | Year over year |
|---|---|---|---|
| Revenue | $21.9B | $21.4B | +2.4% |
| Gross Profit | $14.5B | $14.9B | −2.3% |
| Operating Income | $13.6B | $6.3B | +117.3% |
| Net Income | $11.0B | $3.3B | +237.9% |
JNJ Revenue by Segment
JNJ Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.